IQVIA has impressed industry observers with its Q4 results, which show the potential of the freshly merged company, especially in its technology division. With biotech money and strategic outsourcing as prevalent as it has been in recent memory, could the rest of the CRO industry follow suit? 

ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.

The contract services industry is reaping the rewards of a resilient biotech funding environment, re-accelerating growth in the sector.

When Josef von Rickenbach created Parexel, not only did he create a company, he also helped invent an industry. Now, 35 years later, the Swiss native has stepped aside from CEO to chairman, likening the experience to sending your child to college; painful but ultimately necessary.